Pishdad R et al. published a case report of a patient with a history of Hodgkin’s lymphoma treated with RT who later developed a calcitonin-rich NE carcinoma with a RET translocation, showing an excellent response to Selpercatinib and eventual resistance to it, associated with an activating mutation involving the MEK1 protein (MAP2K1 p. E102-I103 del) that led to relapse and disease progression [57]. Here, MAP2K1 is linked to Hodgkins lymphoma.